What are the limitations of AI in pharmaceutical communications?

Anthony Stackman ·

AI has real limitations in pharmaceutical communications that make it unsuitable as a standalone solution for regulated content. While AI tools can accelerate drafting, summarisation, and research tasks, they cannot replicate the scientific judgement, regulatory awareness, and ethical accountability that pharma communications demand. The questions below explore where those limitations are most consequential for medical affairs, commercial, and marketing teams.

Where does AI consistently fall short in regulated pharma content?

The three areas where AI falls short most consistently are regulatory accuracy, contextual scientific judgement, and accountability. Large language models generate text based on probability patterns, not verified pharmaceutical knowledge. They cannot reliably distinguish between approved label claims and off-label statements, and they have no mechanism to flag when a claim requires substantiation under the ABPI Code, FDA regulations, or EMA guidance.

In practice, this creates several categories of risk for pharma communicators:

  • Claim accuracy: AI may generate plausible-sounding efficacy or safety statements that are not supported by the approved SmPC or prescribing information
  • Regulatory jurisdiction: AI cannot automatically adapt content for different regulatory environments — what is permissible in the US may be restricted in the UK or EU, and AI tools rarely make this distinction reliably
  • Version control: AI has no awareness of which data cuts, trial phases, or label versions are current, making it prone to citing outdated or superseded information
  • Accountability: Regulated pharma content requires a named, qualified signatory. AI has no legal or professional accountability

These are not edge cases. They are structural limitations that apply every time AI is used to generate content that will be submitted for medical-legal review or distributed to healthcare professionals.

Can AI understand the medical and scientific nuance required in pharma comms?

AI can pattern-match and reproduce language that resembles expert writing, but it cannot genuinely interpret clinical and scientific context. In pharmaceutical communications, nuance is not stylistic — it is substantive. The difference between a statistically significant result and a clinically meaningful one, or between a primary endpoint and a post-hoc analysis, carries real consequences for how a medicine is understood and prescribed.

Experienced medical writers and medical affairs professionals make these distinctions instinctively, informed by years of engagement with clinical data, regulatory submissions, and scientific literature. AI tools trained on broad datasets have no equivalent depth. They may reproduce the correct terminology while applying it incorrectly — which is arguably more dangerous than producing obviously wrong content.

There is also the question of therapeutic area expertise. A medical writer specialising in oncology, rare disease, or immunology brings a depth of disease-area knowledge that shapes every editorial decision, from how a mechanism of action is framed to how unmet need is communicated to a payer audience. That depth is not something AI can replicate, and the gap becomes more visible as content complexity increases.

How does AI handle medical-legal review requirements in pharmaceutical advertising?

It does not — because it has no awareness of them. Medical-legal-regulatory (MLR) review is a structured governance process in which qualified medical, legal, and regulatory reviewers assess content against approved labelling, industry codes, and applicable law before any material reaches an external audience. AI operates outside this process entirely and cannot anticipate the questions a reviewer will raise.

This creates a practical problem for teams that use AI to generate first drafts. Content produced by AI may require more substantial revision during MLR review than content written by an experienced medical communicator, because the AI draft may contain:

  • Unsupported comparative claims
  • Promotional language in materials designated as non-promotional
  • Missing or incorrectly applied safety information
  • References that do not support the claims they are cited for
  • Framing that implies efficacy beyond what the evidence supports

Rather than reducing the burden on review teams, AI-generated drafts can increase it. The efficiency gains promised by AI content tools often do not account for the additional review cycles required to bring AI output into a state that is compliant and approvable.

What are the ethical risks of using AI in healthcare communications?

The central ethical risks are accuracy, transparency, and the potential for harm to patients and healthcare professionals who rely on that content to make clinical decisions. In healthcare, communication errors are not simply reputational — they can influence treatment choices, patient understanding, and ultimately clinical outcomes.

Key ethical concerns include:

  • Misinformation at scale: AI can generate and distribute inaccurate health information faster than human review processes can catch it, particularly in digital and social environments
  • Bias in training data: AI models trained on existing medical literature may reproduce historical biases in how diseases are described, which patient populations are centred, and which treatment approaches are presented as standard
  • Transparency and disclosure: There is no settled industry standard for disclosing AI involvement in the creation of healthcare content, creating ambiguity for audiences who may assume human expert authorship
  • Patient-facing content: AI-generated patient materials carry particular risk when they simplify clinical information in ways that are inaccurate or when they fail to reflect individual patient circumstances

Regulatory bodies and professional organisations are beginning to address these questions, but guidance remains fragmented across markets. In 2026, pharma companies operating across the UK, US, and EMEA face the challenge of developing internal AI governance frameworks without a clear, harmonised external standard to follow.

Should pharma companies use AI for medical writing or external expert content?

The short answer is: with significant caution, and only for specific, limited tasks. The distinction between internal drafting and external expert content matters because the two use cases carry very different risk profiles.

For internal drafting tasks, AI can offer genuine utility — summarising published literature, generating structured outlines, producing first drafts of non-promotional internal documents, or reformatting content across different channels. In these contexts, the output is reviewed by qualified professionals before it reaches any external audience, which provides a meaningful safety net.

External expert content is a different matter. Publications, congress presentations, advisory board materials, and key opinion leader programmes all require the authentic scientific voice and intellectual ownership of the named expert. Using AI to generate or substantially shape this content raises questions about authorship integrity, publication ethics, and the validity of the expert’s contribution. Most medical journals and professional bodies now require disclosure of AI use in manuscript preparation, and some explicitly prohibit AI authorship.

The most defensible position for pharma companies in 2026 is to use AI where it demonstrably supports human expertise without replacing it, and to maintain clear internal policies that define where AI involvement is and is not appropriate across the content lifecycle.

How we approach AI in pharmaceutical communications

Our medical communications work is built on human expertise, scientific rigour, and the kind of creative thinking that AI tools cannot replicate. For pharma and biotech clients navigating the genuine complexity of regulated communications, that distinction matters.

  • All medical communications are developed by experienced in-house medical writers and strategists with deep therapeutic area knowledge
  • Content is developed within client governance frameworks, industry codes, and applicable regulatory requirements across the markets where we operate
  • Creative thinking informed by consumer advertising expertise produces communications that are scientifically accurate and genuinely engaging
  • Our services span medical affairs, commercial communications, market access, patient engagement, external expert programmes, congresses, and educational events

If you are reviewing how your organisation uses AI in medical communications and want to understand where human expertise remains essential, speak to our team about how we work.

Related Articles